HomeINOMAX DrugDosing, Administration, and Weaning

Dosing, Administration, and Weaning1


  • For term and near-term neonates with hypoxic respiratory failure, the recommended dosing is 20 ppm
  • Doses greater than 20 ppm are not recommended
  • Maintain treatment for up to 14 days, or until underlying oxygen desaturation has resolved and the neonate is ready to be weaned for INOMAX therapy1


  • INOMAX must be administered using a calibrated FDA-cleared Nitric Oxide Delivery System
  • There are various FDA-cleared Nitric Oxide Delivery Systems (NODS); refer to the NODS labeling to determine which NODS to use with this drug product and for needed information on training and technical support for users of this drug product with the NODS
  • When utilizing the INOmax DSIR® Plus MRI (specifically cleared for use in the MRI suite) only use INOmax MR Conditional cylinders at 100 gauss or less
  • Keep available a backup battery power supply and an independent reserve nitric oxide delivery system
  • Users have access to 24/7/365 customer and technical support provided by Mallinckrodt Pharmaceuticals at 877-566-9466
  • Measure methemoglobin within 4 to 8 hours after initiation of treatment with INOMAX and periodically throughout treatment. Monitor for PaO2 and inspired NO2 during INOMAX administration


Abrupt discontinuation of INOMAX may lead to increasing pulmonary artery pressure and worsening oxygenation even in neonates with no apparent response to nitric oxide for inhalation.1
  • To wean INOMAX, down titrate in several steps, pausing several hours at each step to monitor for hypoxemia
  • If desaturation occurs, reinstate INOMAX immediately